HTG Molecular Diagnostics (HTGM) Issues Quarterly Earnings Results

HTG Molecular Diagnostics (NASDAQ:HTGM) issued its quarterly earnings results on Thursday. The medical research company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.01, Morningstar.com reports. HTG Molecular Diagnostics had a negative net margin of 81.10% and a negative return on equity of 132.67%. The firm had revenue of $4.71 million for the quarter, compared to analyst estimates of $5.14 million. HTG Molecular Diagnostics updated its FY 2018 guidance to EPS.

Shares of HTG Molecular Diagnostics stock traded down $0.49 during trading on Friday, hitting $3.65. 610,059 shares of the stock were exchanged, compared to its average volume of 382,269. The firm has a market capitalization of $118.23 million, a PE ratio of -2.04 and a beta of 2.03. HTG Molecular Diagnostics has a 1-year low of $1.71 and a 1-year high of $5.83. The company has a debt-to-equity ratio of 0.35, a current ratio of 9.50 and a quick ratio of 9.29.

HTGM has been the topic of several recent research reports. ValuEngine lowered shares of HTG Molecular Diagnostics from a “buy” rating to a “hold” rating in a research note on Thursday, July 19th. HC Wainwright set a $7.00 price objective on shares of HTG Molecular Diagnostics and gave the stock a “buy” rating in a research note on Monday, August 6th. Zacks Investment Research upgraded shares of HTG Molecular Diagnostics from a “hold” rating to a “buy” rating and set a $4.00 price objective on the stock in a research note on Tuesday, August 14th. Finally, Cantor Fitzgerald assumed coverage on shares of HTG Molecular Diagnostics in a research note on Thursday, September 20th. They set a “buy” rating and a $7.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $6.25.

Several institutional investors have recently added to or reduced their stakes in the company. FMR LLC increased its stake in shares of HTG Molecular Diagnostics by 0.8% during the 2nd quarter. FMR LLC now owns 3,488,045 shares of the medical research company’s stock worth $11,371,000 after purchasing an additional 27,700 shares during the last quarter. Northern Trust Corp acquired a new position in shares of HTG Molecular Diagnostics during the 1st quarter worth about $189,000. BlackRock Inc. increased its stake in shares of HTG Molecular Diagnostics by 322.8% during the 2nd quarter. BlackRock Inc. now owns 73,044 shares of the medical research company’s stock worth $238,000 after purchasing an additional 55,769 shares during the last quarter. Private Wealth Partners LLC increased its stake in shares of HTG Molecular Diagnostics by 11.1% during the 3rd quarter. Private Wealth Partners LLC now owns 1,000,000 shares of the medical research company’s stock worth $5,050,000 after purchasing an additional 100,000 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new position in shares of HTG Molecular Diagnostics during the 2nd quarter worth about $353,000. Institutional investors own 50.55% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Stock Observer and is the sole property of of Stock Observer. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.thestockobserver.com/2018/11/10/htg-molecular-diagnostics-htgm-issues-quarterly-earnings-results.html.

HTG Molecular Diagnostics Company Profile

HTG Molecular Diagnostics, Inc develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets.

Featured Story: What is Considered a Good Return on Equity (ROE)?

Earnings History for HTG Molecular Diagnostics (NASDAQ:HTGM)

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply